IINN News & Events

Inspira Technologies entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 6,785,715 ordinary shares at a purchase price of $0.70 per share. The gross proceeds to the Company from the offering are expected to be approximately $4.75M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, Inspira will issue and sell unregistered warrants to purchase up to 6,785,715 ordinary shares. The warrants will have an exercise price of $0.70 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date. The offering is expected to close on or about February 6, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Inspira Technologies announced the validation in the Company's advanced blood labs of its Next-Generation Standalone HYLA System. Designed to function independently of the Company's respiratory support devices, this new configuration allows Inspira Technologies to penetrate the broader approximately $50B heart-lung surgery market immediately upon clearance. In advanced bench testing, the system demonstrated 94.2% accuracy for the continuous optical measurement of Partial Pressure of Carbon Dioxide, a performance level that aligns with clinical needs. The validation data confirms that the HYLA optical sensor tracks real-time patient status with high fidelity. The observed 94.2% accuracy for pCO2 is a critical achievement, demonstrating concordance with gold-standard blood gas analyzers within a tight 7 mmHg threshold. By providing continuous, non-invasive visibility into a patient's metabolic status, HYLA eliminates the 'blind spots' associated with intermittent blood draws, potentially reducing complications during heart-lung machine and extracorporeal membrane oxygenation procedures. This validation marks a strategic evolution for the HYLA platform. By decoupling the sensor from Inspira Technologies' life-support hardware, the Company is advancing a standalone system capable of integrating into any existing operating room or ICU workflow. This 'universal compatibility' strategy significantly expands Inspira Technologies's total addressable market and activates a high-margin, recurring revenue model based on the sale of disposable optical sensors and modular software upgrades.

Inspira Technologies announced that its U.S. Food and Drug Administration-cleared INSPIRA ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented: "We view reaching this milestone at one of the nation's leading academic medical centers as a powerful validation of our technology's clinical value and reliability. The ART100 has moved beyond pilot use to standard clinical workflow, driven by repeat utilization and positive physician feedback. With the clinical phase now complete, we are advancing through a defined procurement execution process and view this milestone as a strong validation of our ART100's real-world clinical and commercial readiness."

Inspira Technologies provided an update highlighting progress in the execution of its previously announced binding purchase orders. The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 2025 and August 19, 2025, respectively, have advanced to the final budgetary validation and fund allocation stage within the relevant governmental authorities' procurement processes. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "We continue to work closely with our distribution partners and governmental stakeholders on the execution of these purchase orders. Advancement to the final budgetary stage is a procedural step in complex international procurement processes. We remain focused on converting our contracted backlog into delivered systems and recognized revenue."